Search Results

Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis.

• Authors : Reginster, Jean-Yves; Czerwinski, Edward; Wilk, Krzysztof

Subjects: Biosimilar; CT-P41; Denosumab

• Source: Osteoporosis International (2024-07-23)

Record details

A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.

• Authors : Kim, Anhye; Hong, Jang Hee; Shin, Wonsuk

Subjects: Biosimilar; CT‑P41; denosumab

• Source: Expert Opinion on Biological Therapy, 1 - 9 (2024-02-22)

Record details

Skeletal responses to romosozumab after 12 months of denosumab

• Authors : McClung, M.R.; Bolognese, M.A.; Brown, J.P.

Subjects: anabolic; antiresorptive; denosumab

• Source: JBMR Plus, 5 (7), e10512 (2021)

Record details

Denosumab-induced hypocalcemia in patients treated with dialysis: an avoidable complication?

• Authors : Lloret MJ; Department of Nephrology, Fundació Puigvert, Barcelona, Spain.; Institut de Recerca Sant-Pau (IR-Sant Pau), Barcelona, Spain.

• Source: Clinical kidney journal [Clin Kidney J] 2024 Mar 13; Vol. 17 (3), pp. sfae048. Date of Electronic Publication: 2024 Mar 13 (Print Publication: 2024).Publisher: Oxford University Press Country of Publication: England NLM ID: 101579321 Publication Model: eCollection Cited Medium: Print ISSN:

Record details

Denosumab.

• Authors : Rizzoli R; Yasothan U; Kirkpatrick P

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Osteoporosis/Osteoporosis/Osteoporosis/*drug therapy ; Prostatic Neoplasms/Prostatic Neoplasms/Prostatic Neoplasms/*drug therapy

• Source: Nature reviews. Drug discovery [Nat Rev Drug Discov] 2010 Aug; Vol. 9 (8), pp. 591-2.Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101124171 Publication Model: Print Cited Medium: Internet ISSN: 1474-1784

Record details

Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.

• Authors : Hiligsmann, Mickaël; Boonen, Annelies; Dirksen, Carmen D.

Subjects: Human health sciences; General & internal medicine; Sciences de la santé humaine

• Source: Expert Review of Pharmacoeconomics and Outcomes Research, 13 (1), 19-28 (2013)

Record details

Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium

• Authors : Hiligsmann, Mickaël; Reginster, Jean-Yves

Subjects: Business & economic sciences; Special economic topics (health, labor, transportation...); Human health sciences

• Source: PharmacoEconomics, 29 (10), 895-911 (2011)

Record details

Denosumab STANDs to give patients FREEDOM to DECIDE.

• Authors : Cheeseman, Marie

• Source: Inpharma Weekly. 9/27/2008, Issue 1657, p7-8. 2p.

Record details

Denosumab HALTs bone loss during AI therapy for breast cancer.

• Authors : Ebden, Lucy

• Source: Cancer Today. 1/19/2008, Issue 109, p3-4. 2p.

Record details

Osteoporosis drug licensed for women with high fracture risk.

• Authors : Traynor K

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Bone Density Conservation Agents/Bone Density Conservation Agents/Bone Density Conservation Agents/*therapeutic use ; Fractures, Bone/Fractures, Bone/Fractures, Bone/*prevention & control

• Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2010 Jul 01; Vol. 67 (13), pp. 1046.Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium: Internet ISSN:

Record details